The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2017 | What does the future treatment landscape of myeloma look like?
Michele Cavo, MD, from the Bologna University School of Medicine, Bologna, Italy, discusses ongoing research for multiple myeloma (MM) and penta-refractory disease. Prof. Cavo mentions new drugs and new classes of drugs, such as selinexor and venetoclax, which are currently being tested in clinical trials. He believes the future to be promising as we have new drugs and new classes of drugs to explore, and he expects new information about the status of these drugs to rapidly become available in upcoming meetings.
Recoded at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
